3D Executive Search Partners’ Post

According to DelveInsight’s analysis, the global next-generation complement therapeutics market is expected to experience significant growth, with a projected CAGR of ~15% by 2030. In 2023, the biologics segment held a substantial revenue share within the next-generation complement therapeutics market. Prominent companies in this field, including Roche, Amgen, CSL, Innovent Biologics, Novartis, Regeneron, Sanofi, Takeda, and UCB, among others, are actively contributing to the market’s expansion. Get detailed insights here: https://lnkd.in/dyv8ESNv. #ComplementTherapeutics #Biologics #HealthcareMarket #Pharmaceuticals #MedicalInnovation #MarketAnalysis

CD-20 Market to Witness Significant Growth During the Study Period (2019-2032), Assesses DelveInsight | Major Players – TG Therapeutics, Genentech (Roche), Genmab, Abbvie, Regeneron #Finance #FinancialMarket #MarketingSales #PharmaceuticalsBiotech

MEMBER NEWS: ZyVersa Therapeutics Engages CRO, George Clinical, for Phase 2a Clinical Trial for Cholesterol Efflux Mediator VAR 200 -Cholesterol Efflux MediatorTM VAR 200 is in development to ameliorate renal lipid accumulation that damages the kidneys’ filtration system, leading to chronic kidney disease and its progression. WESTON, Fla., Dec. 14, 2023 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics Inc. Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of patients with renal and inflammatory diseases who have unmet medical needs, announces selection of contract research organization (“CRO”) George Clinical to manage its Phase 2a clinical trial with Cholesterol Efflux MediatorTM VAR 200 in patients with diabetic kidney disease (DKD). The clinical trial is expected to begin in the first quarter of 2024. View full news release: https://lnkd.in/e9v_HMeu

List of FDA Approved Biosimilars (2015-2023) Understanding Biosimilars https://lnkd.in/erQUfwi Approval Process for a Biosimilar https://lnkd.in/ebMEunu Biosimilars Explained https://lnkd.in/eU4jrtC8 Biosimilars and Biologics https://lnkd.in/eQj3Hfkd Biosimilars: Complex Copycat Drugs https://lnkd.in/emiy2Ynx Biosimilars: Are They the Same Quality? https://lnkd.in/e_yaY2Xz What is a Biosimilar? https://lnkd.in/eBi6Zn8 Biosimilar Development Process https://lnkd.in/eGDN65b Prescribing Biosinilar Products https://lnkd.in/exdgupp A biosimilar (also known as follow-on biologic or subsequent entry biologic) is a biologic medical product that is approved based on a showing that it is highly similar to an already-approved biological product, known as a reference product. Biosimilars have no clinically meaningful differences from their reference product in terms of safety, purity and potency. https://lnkd.in/eVx_3DX https://lnkd.in/e29EUrC The biosimilar also must be shown to have no clinically meaningful differences in terms of safety and effectiveness from the reference product. Developed to offer patients additional treatment options, biosimilars are highly similar medications that show no clinically meaningful differences in terms of the safety, purity and potency between themselves and a licensed referenced biologic. They're designed to have a fingerprint like similarity to existing branded biologics. #Cancer #Oncology #biosimilar #biosimilars #BiosimilarProducts #Moffitt #MoffittCancerCenter Moffitt Cancer Center

Less than 3 weeks to go until the 5th Cytokine Based Drug Development Summit in Boston! Join us as we welcome some of the biggest names in the cytokine space, including Pfizer, Regeneron, and Moderna. We can't wait to hear from industry leaders such as Werewolf Therapeutics, Xilio Therapeutics, Inc. & Deka Biosciences, Inc. In the past few months, we've seen some massive deals in the field, including * OSE Immunotherapeutics & AbbVie's agreement for a novel monoclonal antibody for the treatment of chronic inflammation, valued at up to $700 million * Gilead and Xilio also announced an exclusive license agreement for their tumor-activated IL-12 program, with a value of $43.5 million * Sanofi and Synthekine have partnered to develop selective IL-10 agonists for the treatment of inflammatory diseases, a collaboration valued at $40 million. Don't miss out on this incredible opportunity to learn from the best in the field and stay up-to-date on the latest developments in cytokine-based drug development. If you haven't secured your pass yet, fear not. We still have a few passes remaining. Get in touch to secure your attendance before it's too late. jake.bennett@hansonwade.com #cytokines #drugdevelopment #biotech #pharma

Rani Therapeutics has released positive Phase I clinical trial results for RT-111, a biosimilar to ustekinumab (marketed as Stelara by Johnson & Johnson) for psoriasis treatment. RT-111 combines the biosimilar CT-P43 with Rani's non-invasive, 'robotic' RaniPill capsule for drug delivery through the intestinal wall. The study, involving 55 healthy subjects in three cohorts, demonstrated safety and met primary pharmacokinetic endpoints without serious adverse events. Celltrion Inc supplied CT-P43 under a licence and supply agreement with Rani, granting Celltrion first negotiation rights globally. Ustekinumab, an IgG1қ monoclonal antibody, is approved in the US for various conditions, including psoriasis and psoriatic arthritis. Earlier this month, STADA Group and Alvotech won the first EU approval for its Stelara biosimilar Uzpruvo (AVT04), opening the door for more competition to enter the regional ustekinumab market. In addition, Amgen scored the first US Food and Drug Administration (FDA) for its interchangeable biosimilar version of Stelara, dubbed Wezlana (ustekinumab-auub) in November 2023.  #marketintelligence #competitiveintelligence #marketsmind #pharmaceutical #ustekinumab

💊 Johnson & Johnson Acquires Yellow Jersey Therapeutics for $1.25 Billion 💊 Johnson & Johnson expands its biopharmaceutical portfolio with the strategic acquisition of Yellow Jersey Therapeutics for $1.25 billion, securing an innovative eczema treatment, NM26. 🎯 Strategic Acquisition: Johnson & Johnson aims to strengthen its position in dermatological treatments with NM26, targeting two key proteins linked to inflammation and itching. 🔬 Targeted Therapy: NM26, poised for Phase 2 testing, offers potential advantages over existing eczema treatments by addressing both skin inflammation and itching, a unique approach compared to competitors like Dupixent. 💡 Broader Implications: The acquisition reflects J&J's commitment to expanding its immunology portfolio with advanced, dual-targeting therapies, positioning NM26 not only for eczema but potentially other related skin conditions. #JohnsonAndJohnson #J&J #Biopharmaceuticals #EczemaTreatment #InnovationInCare #UpendoStaffing #LoveWhatYouDo

Join the 6th Exosome-Based Therapeutic Development Summit (Sept 17-29, 2024) - https://lnkd.in/gVA7tktR Join the 6th Exosome-Based Therapeutics Development Summit in Boston, MA, this September to delve into groundbreaking advancements, access exclusive clinical data, and forge pivotal partnerships to define the future of exosome drug development. Learn from 30+ renowned speakers from across the development timeline, sharing groundbreaking insights in exosome research including Takeda, Aegle Therapeutics, RION Health, EVerZom and many more. Spanning the complete development cycle of exosome therapeutics from discovery through IND filing, this summit uniquely integrates cutting-edge research with practical commercialization strategies. It stands as a key industry meeting that bridges the gap between science and business, propelling clinical advancements. Don't miss the chance to connect with over 150 of the industry’s leading experts in exosome therapeutics, gain invaluable insights, and place your work at the forefront of pharmaceutical innovation. To learn more, download the Event Guide here: https://lnkd.in/gVA7tktR Will I see you at this summit in September? Let me know in comments below. #exosomes #extracellularvesicles #advancedtherapies Hanson Wade Group Erin Thomas

𝐂𝐨𝐦𝐩𝐚𝐬𝐬 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬 𝐑𝐞𝐜𝐞𝐢𝐯𝐞𝐬 𝐅𝐃𝐀 𝐅𝐚𝐬𝐭 𝐓𝐫𝐚𝐜𝐤 𝐃𝐞𝐬𝐢𝐠𝐧𝐚𝐭𝐢𝐨𝐧 𝐟𝐨𝐫 𝐂𝐓𝐗-𝟎𝟎𝟗 𝐢𝐧 𝐀𝐝𝐯𝐚𝐧𝐜𝐞𝐝 𝐁𝐓𝐂 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 Compass Therapeutics (Nasdaq: CMPX) Compass Therapeutics Inc. announces FDA Fast Track Designation for CTX-009, a bispecific DLL4/VEGF-A antibody, in combination with paclitaxel for metastatic or locally advanced BTC patients previously treated. CEO Thomas Schuetz expresses excitement, citing the critical need for effective treatments in advanced BTC, where current therapies show limited efficacy. Promising Phase 2 results include a 37.5% overall response rate and favorable survival outcomes. Enrollment completion and top-line data expected by year-end. #CompassTherapeutics #FDA #FastTrackDesignation #AdvancedBTC #CancerResearch #Biopharmaceuticals #MedicalInnovation

The field of drug development is constantly evolving. From new #cancer treatments to innovative therapies for liver and #neurological conditions, new advancements in #pharmaceuticals represent significant strides in #medical science. Discover more about the groundbreaking drugs from Astellas Pharma, Madrigal Pharmaceuticals, and Karuna Therapeutics (BMS) that are set to transform patient care in the coming years. Check out our complete report on the Healthark Insights website - https://lnkd.in/ehCi-ZQG #Pharmaceuticals #DrugApproval #MedicalInnovation #ClinicalResearch #NewTherapies #LifeSciences #FutureOfMedicine #PatientCare #FDAApproval